Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 42%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc. demonstrates a solid outlook due to a significant increase in Chromium reaction volumes, indicating strong market resilience despite ongoing pricing pressures. The company is projected to see substantial growth in consumables, with estimates ranging from 5 to 19 times per platform by the year 2027, outpacing instrument revenue growth. This robust demand for consumables suggests sustained relevance and a competitive edge in the life sciences technology sector amid challenges in pharmaceutical spending.

Bears say

10x Genomics Inc has experienced significant contraction, with a decline in revenues attributed to double-digit pricing pressure and flat to modestly lower volumes, with growth not expected to resume until 2027. The company reported an EPS miss of -$0.40 compared to the expected -$0.30 for the fourth quarter, alongside a full-year revenue outlook that fell below expectations. Additionally, despite market expansion since the peak stock prices in 2021, the growth has not met analysts' expectations, leading to a stock price decline of over 90% since that peak.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 42% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Buy based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.